Evolution of Regulation for Rare Disease Drugs in Brazil

ANVISA regulation boosts approval of drugs for rare diseases in Brazil.

Understand how ANVISA’s regulation has accelerated the approval of drugs for rare diseases and the impact on international manufacturers. Health regulation in Brazil has undergone significant advances in recent years. One of the most impacted sectors is medicines for rare diseases, which registered a significant growth in the number of approvals by ANVISA. In the […]

Regularization of Cannabis-Based Products for Veterinary Use

Illustrative image on the regulation of Cannabis products for veterinary use according to ANVISA and MAPA.

Understand how the new measure impacts the regulation of veterinary products and how QR Group can help companies in the process. On October 30, ANVISA’s Collegiate Board approved a measure that allows the regularization of cannabis-based products for veterinary use by the Ministry of Agriculture and Livestock (MAPA). The decision amends Ordinance SVS/MS 344/1998, allowing […]

Elevidys® Approval by ANVISA: The Impact of Gene Therapy for Duchenne Muscular Dystrophy

Approval of Elevidys® by ANVISA for the treatment of Duchenne Muscular Dystrophy, innovative gene therapy.

Understand the Approval of Elevidys and How QR Group Assists® in the Registration Process of Innovative Products in Brazil The approval of Elevidys® (delandistrogen moxeparvoveque) by ANVISA for the treatment of Duchenne Muscular Dystrophy (DMD) represents a milestone in the area of advanced therapies in Brazil. QR Group, with its expertise in medical device and […]

QR Group Explains Anvisa’s New Rules for Importing Medical Device Components

ANVISA update on the import and storage of medical device components – RDC 860/2024 and 939/2024

Understand how the updates to RDCs 860/2024 and 939/2024 impact the import and storage of medical device components and accessories in Brazil Anvisa has updated the processes and flows related to the import and storage of medical device components. With the recent publication of Collegiate Board Resolutions (RDCs) 860/2024 and 939/2024, importers need to understand […]

Update on Smoking Product Registration and Renewal: What Companies Need to Know

ANVISA guidelines on registration and renewal of smoking products according to RDC 896/2024

Understand how the update of ANVISA’s guidelines affects the registration and renewal of smoking products and how QR Group can help in the process. ANVISA recently updated its guidelines on the registration and renewal of smoking products derived from tobacco. This change is included in the Collegiate Board Resolution (RDC) 896/2024, which reformulates the requirements […]

ANVISA’s Participation in WHO: Impacts on the Regulation of Medical Products

WHO meeting discusses regulation of counterfeit medical products with participation of ANVISA.

Understand the Importance of ANVISA’s Role in the Global Product Regulation ANVISA is participating in the 13th plenary meeting of the Member States Mechanism on Substandard and Falsified Medical Products (MSMSF) of the World Health Organization (WHO), reinforcing its essential role in product regulation at the international level. The event will take place between November […]

Anvisa Prioritizes Registration of Tests for Arboviruses, Including Dengue and Chikungunya

Diagnostic tests for dengue and other arboviruses being evaluated by scientists.

Anvisa is implementing measures to speed up the registration of diagnostic tests for mosquito-borne diseases, aiming at better control of arboviruses in Brazil. The National Health Surveillance Agency (Anvisa) recently announced that it will prioritize the analysis of requests for registration of tests for the diagnosis of mosquito-borne diseases, such as dengue, chikungunya and oropouche […]

QR Group Explains Data Sharing Agreement Between Anvisa and FDA

Representatives from Anvisa and FDA signing an agreement to exchange data on medicines.

Understand how the new agreement between Anvisa and the FDA can speed up drug approval in Brazil and how QR Group can help your company comply. The National Health Surveillance Agency (Anvisa) and the Food and Drug Administration (FDA), the regulatory body in the United States, have signed an important confidentiality agreement that will facilitate […]

Simplifying the process: regularizing products at ANVISA

Product regularization at ANVISA with support from QR Group.

Understand the essential steps for regularizing products with ANVISA and how QR Group can help your company ensure compliance quickly and safely. If you work in the industry of products that require regularization with the health surveillance agency, you know that regularizing products with ANVISA is a crucial step, not only for marketing, but also […]

QR Group Explains the Impact of the Mais Médicos Program in Brazil

QR Group explains how the Mais Médicos Program increases vacancies for professionals with CRM Brazil.

Understand how the Mais Médicos program is strengthening healthcare in Brazil, with 95% of vacancies filled by professionals trained in the country and the growing participation of quota holders The Mais Médicos program, which has reached its 38th cycle, continues to expand access to healthcare in Brazil, filling 95% of new vacancies with professionals trained […]